Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Smoldering Multiple Myeloma 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Kidney Neoplasms 1

Interventions

Dexamethasone 33Cyclophosphamide 28Melphalan 26Specimen Handling 24Biopsy 24Bortezomib 23Magnetic Resonance Spectroscopy 17Calcium Dobesilate 17fludarabine phosphate 15Lenalidomide 15Filgrastim 15Vincristine 12Prednisone 12Peripheral Blood Stem Cell Transplantation 12sargramostim 9dexamethasone acetate 9dexamethasone 21-phosphate 9carfilzomib 9auricularum 9Doxorubicin 9fludarabine 8Thalidomide 8Interferon-alpha 7Cyclosporine 7Busulfan 7trametinib 6Rituximab 6Etoposide 6ixazomib 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Multiple Myeloma × AH 111585 × Clear all
NCT01571726 2019-12-16

Imaging Studies and the Development of Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡